AI-Driven Tumor Type Prioritization Strategy Case Study

This case study details the collaboration between ZS and Intelligencia AI, focusing on a global pharmaceutical company's strategy for solid tumor portfolio planning. The objective was to establish a long-term strategy for the next 5–10 years, moving beyond traditional science-led approaches to a more systematic and commercially informed perspective of the oncology landscape. The study outlines core challenges such as defining focus areas, making data-driven decisions, and scaling analysis while minimizing manual efforts. Key outcomes included a sharper focus on prioritized solid tumors, faster decision-making through harmonized data, and broader organizational impact with increased engagement from Medical and R&D teams. The engagement utilized Intelligencia AI's Portfolio Optimizer, which provided a transparent and explainable assessment of technical and regulatory success probabilities. This approach not only enhanced decision-making but also addressed internal biases, resulting in a rigorous, data-driven perspective that informed strategic choices and painted a competitive landscape.